Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders (2016 - 2020)
Historic Net Income towards Common Stockholders for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' Net Income towards Common Stockholders fell 3980.99% to -$19.9 million in Q4 2020 from the same period last year, while for Sep 2021 it was -$19.9 million, marking a year-over-year increase of 6980.29%. This contributed to the annual value of -$318.8 million for FY2024, which is 5225.35% down from last year.
- According to the latest figures from Q4 2020, Syndax Pharmaceuticals' Net Income towards Common Stockholders is -$19.9 million, which was down 3980.99% from -$19.9 million recorded in Q3 2020.
- Syndax Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$8.4 million for Q2 2016, and its period low was -$19.9 million during Q4 2020.
- Over the past 5 years, Syndax Pharmaceuticals' median Net Income towards Common Stockholders value was -$15.1 million (recorded in 2017), while the average stood at -$15.4 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 14593.4% in 2016, then soared by 2652.46% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$10.9 million in 2016, then plummeted by 74.99% to -$19.0 million in 2017, then fell by 1.61% to -$19.3 million in 2018, then rose by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
- Its last three reported values are -$19.9 million in Q4 2020, -$19.9 million for Q3 2020, and -$16.6 million during Q2 2020.